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TRPC6, a member of the canonical transient receptor potential channel (TRPC) subfamily, is an important cation selective ion
channel on podocytes. Podocytes are highly diﬀerentiated cells located on the visceral face of glomerular basement membrane
and featured by numerous foot processes, on which nephrin, podocin, and TRPC6 locate. Podocytes and the slit diaphragm (SD)
between adjacent foot processes form a selective ﬁltration barrier impermeable to proteins. TRPC6 is very critical for normal
podocyte function. To investigate the function of TRPC6 in podocytes and its relation to proteinuria in kidney diseases, we over-
expressed TRPC6 in podocytes by puromycin aminonucleoside (PAN) and observed the changes of foot processes, TRPC6 protein
distribution, and mRNA expression. Accordingly, in this study, we further investigated the role of speciﬁc signaling mechanisms
underlying the prosurvival eﬀects of dexamethasone (DEX) on podocyte repair. Our results showed that podocytes processes
of overexpressing TRPC6 were reduced remarkably. These changes could be rescued by DEX via blocking TRPC6 channel.
Additionally, our results also showed an improvement in TRPC6 arrangement in the cells and decrease of mRNA expression
and protein distribution. From these results, we therefore proposed that overexpression of TRPC6 in podocytes may be one of the
fundamental changes relating to the dysfunction of the SD and proteinuria. DEX may be maintained the structure and function
integrity of SD by blocking TRPC6 signal pathway and played an important role in mechanisms of anti-proteinuria.
1.Introduction
TRPC6 is determined in recent years which is closely related
with proteinuria and positioned in the structure protein
molecules of SD. Proteinuria is a common feature of kidney
dysfunction of glomerular origin and is itself a risk factor for
renal disease [1]. There is a growing body of experimental
and clinical literature showing that podocyte number is
a critical determinant for the development of proteinuria
and glomerulosclerosis [2] .P A Ni su s e dt oi n d u c eaw e l l -
established cell model for podocytes injury. DEX is widely
used for the treatment of a variety of glomerular diseases
characterized by podocyte injury and proteinuria, including
membranous nephropathy, minimal change disease, FSGS,
and lupus nephritis. However, the signaling mechanisms
underlying the antiproteinuria eﬀects of DEX have not been
well deﬁned. In this study, we further investigated the role
of speciﬁc signaling mechanisms underlying the protection
eﬀects of DEX on podocyte injury. Our results showed
that, in podocytes overexpressing TRPC6, cell processes were
reduced remarkably. These changes could be rescued by the
treatment of the cells with DEX to block TRPC6 channel.
Additionally, the podocytes overexpressing TRPC6 treated
with DEX showed an improvement in TRPC6 arrangement
in the cells and decrease of mRNA expression and protein
distribution.
2.MaterialsandMethods
2.1. Cells in Culture. Conditionally immortalized mouse
podocyte clone (a kindly gift from Professor Peter Mundel,
USA, and Professor Jie DING, Peking University First
Hospital) was cultured at 33◦C in RPMI-1640 containing
10% fetal bovine serum (Gibco, Gaithersburg, MD, USA),
100U/mL penicillin/streptomycin, and 10U/mL of mouse
recombinant r-interferon (PEPRO Tech, London, UK) and
then shifted to 37◦Cf o rd i ﬀerentiation by removal of r-
interferon[3].hadtypicalcharacterofmaturepodocyteafter2 Evidence-Based Complementary and Alternative Medicine
two weeks. In the studies described below, all experiments
were performed in growth-restricted podocytes.
2.2. Experimental Design. In order to examine the eﬀect of
DEX on PAN-induced podocyte injury, podocytes grown
under growth restrictive conditions for 12 days were incu-
bated with media containing 10% FBS in the presence of
1μmol/L DEX (Sigma Chemical Co). DEX was not removed
until the end of each experiment. To determine if DEX
reduced a range of injuries, the following experiments were
undertaken after 1h of DEX incubation: PAN. To determine
the mechanisms of podocyte injury induced by PAN, we
exposed podocytes to PAN (Sigma Chemical Co) at a
concentration of 50μg/mL. Following a 48h incubation with
PAN in the presence or absence of DEX, then observed and
harvestedat8h,24h,and48h,respectively.Theexperiments
were all repeated three times.
2.3. RT-PCR Analysis. Total RNA was extracted from
podocyte using Trizol reagent according to the man-
ufacturer’s instruction, and the RNA concentration was
determined after the sample was dissolved in diethyl-
pyrocarbonate-treated water. Isolated RNA (1μg) of each
sample was subjected to reverse transcription by using
Rever Tra Ace (TOYOBO Co., Japan) according to the
manufacture’s protocol. The resulting cDNA (3μL) was
used for PCR ampliﬁcation. The sequence-speciﬁc primers
were designed and synthesized by Shanghai Invitrogen
Biotechnology Co, Ltd. Primers used were as follows. TRPC6
upstream and downstream primers, respectively, were as
follows. Forward: 5 GTTAATTGCGATGATCAATAGTT-3.
Reverse: 5-GACTTGGTACAAGATTGAAGG-3. Probe: 5-
FAM-CCAGGAAATTGAGGATGATGCGGACGTG-BHQ1-
3, product length being 143bp. GAPDH upstream and
downstream primers were as follows. Forward: 5-GGTG
AAGGTCGGTGTGAACGGAT-3. Reverse: 5-CCACTTTGC
CACTGCAAATGGCAG-3. Probe: FAM-CTGGTGACCAG
GCGCCCAATACGGCC-BHQ1, product length being
118bp. The PCR ampliﬁcation was started with 2min of de-
naturation at 94◦C, which was followed by 34 cycles (for
GAPDH, 30 cycles) of denaturation at 94◦Cf o r3 0 s ,
annealing at 55◦C for 30s (GAPDH, 55◦Cf o r3 0 s ) ,a n d
polymerization at 72◦C for 75s (GAPDH, 30s). The ﬁnal
extension lasted 7min at 72◦C and then ended at 4◦C. PCR
products (5μL) were separated on 1% ethidium bromide-
stained agarose gels and later scanned with gel imaging
system (Bio Rad Company A). Independent experiment was
repeated 3 times.
2.4. Western Blot Analysis. Podocytes were lyzed in the buﬀer
containing 1% Tritonx-100, 150mM NaCl, 1mM EDTA,
50mM Tris-HCl (pH 7.7), 1mM NaF, 1mM NaVO3, and
a protease inhibitor cocktail (Sigma Chemical Co). Seventy-
ﬁve micrograms of total protein was loaded to run 8%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE), and the gel was set up for transfer protein
to nitrocellulose membranes (Sigma Chemical Co.). Then,
the membranes were rinsed in a Tris-buﬀered saline with
0.02% Tween-20 (TTBS), followed by immersing in 5% low-
fat milk. Subsequently, the membranes were incubated with
rabbit anti-TRPC6 antibody (Sigma Chemical Co); mouse
anti-GAPDH antibody (Sigma Chemical Co). After rinsing
three times with TTBS, the membranes were incubated
with HRP-conjugated goat anti-rabbit or mouse IgG (Sigma
Chemical Co.) for 45min at room temperature and then
developed using ECL chemiluminescence reagent (Sigma
Chemical Co.). The speciﬁc protein bands were scanned and
quantitated using densitometry in relation to the GAPDH,
WesternBlottingDetectionSystem(GEHealthcare,Chalfont
St. Giles, UK). We repeated each Western Blot analysis using
protein from three diﬀerent and separate experiments.
2.5. Immunostaining. TRPC6 was ﬁxed with 4% par-
aformaldehyde, then permeabilized, and blocked with 0.3%
TritonX-100 and 5% bovine serum albumin. The primary
antibody,rabbitanti-TRPC6antibody(SigmaChemicalCo),
was applied for overnight at 4◦C. FITC-conjugated goat anti-
rabbitormouseIgG(SigmaChemicalCo)andthenucleidye
Hoechst were used for 45min at room temperature. Finally,
the coverslips were mounted and images were taken by
using a immunoﬂuorescence microscope (Zeiss, Germany).
To determine the percentage of the cells in which RPC6 is
localized in nuclei, we counted at least 200 nuclei in triplicate
in each experiment.
2.6. Statistical Analysis. Data were reported as mean ± SD
with n equal to the number of experiments. Statistical
evaluation was performed using a one-way ANOVA (two-
sided test), followed by LSD (equal variances assumed) or
Dunnett’s T3 (equal variances not assumed) for post hoc test
between two groups, and also using the nonparametric tests
(Mann-WhitneyU-test)asaposttest.ValuesofP<0.05were
considered as statistically signiﬁcance.
3. Results
3.1. Eﬀect of DEX on PAN-Induced Podocytes Changes.
Podocytes were observed and photographed under inverted
microscope. The relative area of podocytes was calculated
by Image J and SPSS 13.0. The cell bodies and nucleus of
PAN-induced podocytes were signiﬁcantly decreased. The
cell bodies, which connected to each other between cells,
stretched out like the branches. Foot processes appeared
retraction, and the area of PAN-inducted podocytes was
signiﬁcantly reduced to 75% at 8h (P<0.05); foot processes
was obviously retracted, and the cell bodies were reduced
to 46% at 24h (P<0.01); shrinked to 27% (P<0.01),
part of foot processes occurred disappearance or lost at
48h. However, after DEX treated, the area of podocytes was
signiﬁcantly greater at 8h, 24h, and 48h, the diﬀerence was
signiﬁcant (P<0.05). Based on these ﬁndings, we developed
the hypothesis that PAN-induced injury maybe prevented by
DEX. Figure 1.
3.2. Eﬀect of DEX on Pan-Induced TRPC6 mRNA Expression.
TRPC6 mRNA results showed that the target bands can beEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: PA-induced podocytes changes at diﬀerent time points (inverted-phase contrast microscope ×200). Note: (a, d, g): the control
group, 8h, 24h, 48h, resp., (foot processes and the connection between podocytes are intact) (b): PAN-induced 8h; (c): DEX-treated 8h;
(e): PAN-induced 24h; (f): DEX-treated 24h; (h): PAN-induced 48h (foot process retracted and lost, cell interconnected disappeared); (i):
DEX-treated 48h (foot processes and the connection between podocytes are still preserved).
seen in the 3rd and 4th lanes (150bp). Our studies showed
that there was Trpc6 mRNA expression in the 3rd and 4th
samples,buttheexpressionislow,andsuggestedthatTRPC6
mRNA expression is very low under normal circumstances
and cannot be shown by the agarose gel electrophoresis.
TRPC6 mRNA expression did not change signiﬁcantly at
PAN-induced 8h and 24h. But TRPC6 mRNA expression
signiﬁcantly increased at 48h (P<0.01); TRPC6 mRNA
expressiondidnotshowsigniﬁcantlychangesatDEX-treated
8h;theTRPC6mRNAexpressionwassigniﬁcantlydecreased
at 24h and 48h (P<0.01). Figure 2(a).
Under normal circumstances, TRPC6 expression is very
low in podocytes. GAPDH as internal control, Compared
withthecontrolgroup,foundthatTRPC6mRNAexpression
was not signiﬁcantly changed after PAN-induced 8h. But
TRPC6 mRNA expression slightly increased at 24h and 48h
(P<0.05); TRPC6 mRNA expression signiﬁcantly decreased
after DEX-treated 8h, 24h, and 48h (P<0.05), Figures 2(b)
and 2(c).
3.3. Eﬀect of DEX on PA-Induced TRPC6 Protein Expression.
Western Blot analysis showed that TRPC6 and GAPDH,
respectively, have speciﬁc band at 36kd and 106kd. Under
normal circumstances, podocytes have a certain amount
of TRPC6 protein expression. Compared with the control,
TRPC6 protein expression did not change signiﬁcantly at
PAN-induced 8h but was higher at 24h and 48h (P<0.01);
TRPC6 protein expression did not signiﬁcantly change at
DEX-treated 8h; decreased at 24h; became normal (P<
0.05). The protein expression signiﬁcantly decreased at 48h
(P<0.01), Figures 3(a) and 3(b).4 Evidence-Based Complementary and Alternative Medicine
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Figure 2:(a)TRPC6mRNAexpressionchangesatdiﬀerenttimepoints.Note:1,4,7-8h;2,5,8–24h;3,6,9–48h.(b)GAPDHampliﬁcation
map. (c) TRPC6 ampliﬁcation map. Note: there was a slight peak in 3rd and 4th samples, ct value reached 34.77, 34.69, indicated that there
was Trpc6 mRNA expression in the 3rd and 4th samples, but the expression is low.
3.4. Eﬀect of DEX on PAN-Induced TRPC6 Distribution
Changes in Podocytes. TRPC6 was linear and evenly dis-
tributed in the control, little in the cytoplasm; at PAN-
inducted 24h, TRPC6 was not continuity distribution
along the cell membrane, increased in cytoplasm; at 48h,
TRPC6 distribution increased in cell membrane, part of
the cell membrane lost or gathered into granular, widely
distributed in cytoplasm. But, after DEX-treated, TRPC6,
whichsigniﬁcantlyimprovedatdiﬀerenttimepoints,ismore
homogeneous distribution in the plasma membrane and
became normal. Figure 4.
4. Discussion
TRPC6 is a member of the large transient receptor potential
superfamily of nonselective cation channels [4, 5]. This
superfamily consists of a group of six transmembrane
domain-containing ion channels and has been subdivided
into six subfamilies; TRPC3; TRPC6, and TRPC7 have about
75% homology, together constitute heteromeric polymer,
and form the function channel [6]. Firstly, Winn et al. [7]
and Reiser et al. [2], in 2005, determined one of the
pathogenic genes of causing familial focal segmental glom-
erulosclerosis (FSGS). Further studies showed that there
was interaction between TRPC6 protein and SD molecules,
together constituting the diaphragm hole complex. This
ﬁnding will make podocyte structural proteins and ion
channels linked. Recent studies have also shown that TRPC6
is expressed in foot processes. TRPC6 within the cell body
of podocytes and in primary processes in close vicinity to
SD was associated with the nephrin, podocin, and CD2AP
[8]. TRPC6 is a component of the SD multiprotein complex,
involved in the physiologic and pathophysiologic role of
podocytes [9].
Glucocorticoids are widely used for the treatment of
glomerular diseases characterized by podocyte injury and
proteinuria [10]. It has been speculated that glucocorticoids
exert therapeutic eﬀects through their immunosuppressive
andanti-inﬂammatorymechanisms[11].Footprocessesand
SD contribute to the formation of the glomerular ﬁlter.
It plays an important role in maintaining the podocyte
function. Podocyte injury may result in a leakage of proteins
into the urine. So injury to podocytes and their SD typically
leads to marked proteinuria. PAN, a podocyte toxin, is wildly
usedtoinduceexperimentalnephroticsyndromeinrats[12–
14], In in vitro study, PAN results in foot process eﬀacement
and variable dose-dependent apoptosis [15]. As a new SD
molecule, TRPC6 is an important molecule for keeping the
structure and function of podocytes as well as regulation
of signaling transduction in podocytes and interacting withEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: (a) The Western Blot band of TRPC6 and GAPDH at
diﬀerent time points. Note: (1) the control; (2) PAN stimulation;
(3) DEX intervention. (b) The Western Blot analysis of TRPC6 and
GAPDH at each time point. Note: the Western Blot analysis showed
that the protein level of TRPC6 was increased at PAN-induced 24h
and 48h, the diﬀerence was signiﬁcant, P< 0.01; the protein
level of TRPC6 was decreased at DEX-treated 24h and 48h, the
diﬀerence was signiﬁcant, P< 0.05.
other SD molecules, such as nephrin, podocin, and CD2AP
[16–18]. Reiser et al. found that TRPC6 was expressed at the
podocyte membrane.Innongeneticformsofglomerulardis-
ease, such as minimal change disease (NCD), membranous
glomerulonephritis (MGN), and FSGS, TRPC6 overexpre-
sioncandirectlyaﬀectcytoskeletalorganizationinpodocytes
[19]. M¨ oller et al. also observed that TRPC6 overexpression
correlated with the development of podocyte injury. All of
these suggest that TRPC6 overexpression is a pivotal factor
resulting in podocyte injury. In the PAN-injected rats, the
TRPC6 levels were increased markedly [19]. Knocking-down
TRPC6 could eﬀectively prevent the podocytes apoptosis
induced by PAN [12]. PAN results in foot process eﬀacement
and variable dose-dependent apoptosis [20, 21]. On the
basis of these ﬁndings, we hypothesized that TRPC6 would
also take part in the PAN-induced podocyte injury. DEX
resisted podocyte injury via stabilizing TRPC6 expression
and distribution. The major purpose of our study was to
determine whether DEX mediated the speciﬁc cytoprotective
eﬀect by blocking TRPC6-signaling pathway and blocking
TRPC6 channels maybe beneﬁcial to protect podocytes from
injury.
Our study found that, at PAN-induced and DEX-treated
8h, TRPC6 had no signiﬁcant changes in protein expression.
but was signiﬁcantly higher at PAN-inducted 24h and 48h
(P<0.01); TRPC6 protein expression was signiﬁcantly
d e c r e a s e da tD E X - t r e a t e d2 4 ha n d4 8 h( P<0.05).
Immunoﬂuorescence staining suggested that TRPC6 showed
a linear uniformly distribution in the control group, only
a little in the cytoplasm; at PAN-inducted 24h, TRPC6
was mainly punctate distribution along the membrane
and increased in cytoplasmic. At 48h, TRPC6 distribution
increased in the cell membrane, part lost, gathered into
a granular, widely distributed in the cytoplasm; TRPC6
was more homogeneous distribution after DEX treatment.
The distribution was signiﬁcantly weaker in cytoplasm.
The diﬀerence, which is compared with other podocyte
molecules, was that TRPC6 expression strengthened in PAN-
inducted podocytes, the distribution increased but reduced
after DEX-treated. This is the special position of TRPC6 as
a cation channel protein. But the speciﬁc mechanism is not
very clear, pending further study. Our results suggested that
TRPC6 might be a pharmacological target of maintaining
the function of podocytes in the future. So blocking TRPC6
channels may be a new therapeutic strategy in proteinuric
renal diseases.
Our evidence also suggests that blocking TRPC6 chan-
nelsmaybeoftherapeuticbeneﬁtinproteinuria.Thiscreates
the exciting possibility that blocking TRPC6 channels within
the podocyte may translate into long-lasting clinical beneﬁts
inpatientswithFSGS.OurstudysuggestedthatTRPC6ﬁlled
the damage signal, which was induced by PAN, and then
activatedthedownstreammolecules,causedtheinjurysignal
transduction, so that foot process responds to retracted
and lost. TRPC6 abnormal expression and distribution
led to imbalance of TRPC6 channels and function. The
changes of podocyte ﬁltration rate caused the occurrence
of proteinuria; the DEX may have made the downstream
molecules, which have been activated, inactivated, podocytes
restored their original structure by blocking TRPC6 signal
channels, thus maintained SD structural and functional
integrity by stabilizing TRPC6 expression, and played a
protective role in anti-proteinuria.
In summary, TRPC6 overexpression may be one of the
fundamental changes in podocytes leading to proteinuria
and impairment of renal function. Perhaps, blocking the
TRPC6 channel may be candidate for diagnosis and ther-
apeutic target of renal diseases. Our study suggested that
TRPC6 signal pathway participated in the signal trans-
duction mechanisms of DEX inhibiting podocyte injury
induced by PAN. DEX stabilized TRPC6 expression through
binding to its receptor. Our study will provide more clearly
theoretical basis for the molecular mechanism of DEX
antiproteinuriaandalsoprovidenewinsightsintothespecial
beneﬁcial eﬀects of DEX on podocyte injury.6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Eﬀects of DEX and PAN on the distribution and protein expression of TRPC6 at diﬀerent time points (ﬂuorescencemicroscope
×400). Note: (a, d, g) were the control group, TRPC6 was linear and evenly distributed in the podocytes membrane surface, there are
some distribution in the cytoplasm; (b) PAN-inducted 8h; (e) PAN-inducted 24h, TRPC6 was not continuity distribution along the cell
membrane, increased in the cytoplasm; (h) after PAN-inducted 48h, TRPC6 distribution increased in the cell membrane, part of the cell
membrane lost, gathered into a granular, widely distributed in the cytoplasm; (c) PAN-inducted + DEX-treated 8h; (f) PAN-inducted +
DEX-treated 24h; (i) PAN-inducted + DEX-treated 48h, TRPC6 was more homogeneous distribution in the membrane at each time point.
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